Antiverse, a pioneering UK-based AI-driven techbio company, has successfully closed a $9.3 million Series A financing round. This substantial investment, led by Soulmates Ventures, will significantly accelerate its mission to design therapeutic antibodies for historically challenging disease targets. The funding underscores growing confidence in Antiverse's innovative approach to drug discovery, aiming to address critical unmet medical needs.
Advancing AI-Driven Antibody Discovery
The Series A round, bringing total funding to over $20 million since inception, saw participation from Innovation Investment Capital, DOMiNO Ventures, and existing investors DBW, Kadmos Capital, and i&i Biotech Fund. This diverse investor base highlights the broad appeal and potential of Antiverse's technology. The capital infusion positions the company for substantial growth and impact in the biopharmaceutical sector.
This crucial financing will enable Antiverse to significantly scale its AI-powered antibody discovery platform for pharmaceutical and foundation partners. It will also support the robust expansion of the company’s internal drug pipeline. Furthermore, the funds will advance lead antibody programs toward critical in vivo efficacy studies, accelerating their path to clinical development.
Tackling "Undruggable" Targets
A major hurdle in modern medicine involves treating diseases linked to "undruggable" molecular targets, which often leads to high attrition rates in drug discovery. Approximately 90% of drug candidates fail to reach approval in clinical trials, highlighting the urgent need for novel approaches. Antiverse directly addresses this gap by focusing on these complex and elusive targets.
Antiverse's AI-led computational platform is specifically designed to generate therapeutic antibodies against challenging targets like G-protein coupled receptors (GPCRs) and ion channels. These targets are implicated in severe conditions, including cancer, neurological disorders, and rare genetic diseases such as cystic fibrosis. Their innovative technology offers new hope for patients with limited treatment options.
The Lab-in-the-Loop Advantage
Antiverse distinguishes itself by combining advanced machine learning with proprietary in-house laboratory validation, creating a unique "lab-in-the-loop" workflow. This integrated approach allows for the rapid design and testing of antibody candidates. The company's models generate antibodies for specific disease targets, which are then built and evaluated efficiently.
Proprietary cell systems replicate how target proteins appear in the human body, ensuring realistic and relevant testing conditions. This iterative process enables faster cycles between computational design and experimental validation, significantly improving antibody discovery efficiency. Candidates showing promising results are subsequently advanced toward clinical development with greater confidence.
Strategic Collaborations and Impact
Antiverse has forged a significant research agreement with the Cystic Fibrosis Foundation (CF Foundation) to design novel antibodies. This collaboration targets the extracellular region of the CFTR protein, a historically difficult target in cystic fibrosis research. The partnership aims to accelerate the evaluation of new therapeutic approaches for this debilitating genetic disease.
Murat Tunaboylu, Co-Founder and CEO of Antiverse, emphasized the importance of the financing. He stated that it enables scaling their generative antibody design platform and expanding strategic collaborations, such as their work with the Cystic Fibrosis Foundation. These efforts collectively inform future research and advance Antiverse's therapeutic programs for patients.
Investor Confidence and Future Outlook
Michal Sikyta, Managing Partner at Soulmates Ventures, praised Antiverse's capabilities, noting their ability to reduce de novo therapeutic antibody development time to under four months. He highlighted this as a significant scientific and operational achievement in drug discovery. Sikyta believes Antiverse is poised to become a global leader in developing therapies for elusive disease targets.
Antiverse has already secured partnership agreements with multiple top-20 global pharmaceutical companies, including Nxera, demonstrating strong industry validation. The company now aims to progress its first wholly owned candidates into later-stage preclinical development by 2027. Concurrently, Antiverse will continue supporting pharmaceutical partners with their antibody discovery programs, solidifying its market position.
This successful Series A funding marks a pivotal moment for Antiverse, empowering its innovative AI-driven platform to tackle some of medicine's most persistent challenges. By combining cutting-edge machine learning with rigorous laboratory validation, Antiverse is poised to revolutionize antibody discovery for "undruggable" targets. The company's advancements promise to bring much-needed therapeutic options to patients worldwide.